---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-125374"
form_type: "8-K"
ticker: "XENE"
cik: "0001582313"
company_name: "Xenon Pharmaceuticals Inc."
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T01:54:50.343743+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Xenon Q3 2024 net loss $62.8M; X-TOLE2 topline data expected H2 2025; COO appointed

## Summary
- Net loss of $62.8M for Q3 2024, compared to $48.5M in Q3 2023; R&D expenses rose to $57.0M.
- Cash and marketable securities $803.3M as of Sep 30, 2024; cash runway expected into 2027.
- Phase 3 X-TOLE2 focal onset seizure study topline data anticipated in H2 2025.
- Phase 3 MDD study X-NOVA2 expected to initiate by end of 2024.
- Appointed Matt Ronsheim as COO, new senior executive; early-stage pipeline targeting multiple INDs in 2025.

## SEC filing metadata
- accession: 0000950170-24-125374
- form_type: 8-K
- ticker: XENE
- cik: 0001582313
- company_name: Xenon Pharmaceuticals Inc.
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1582313/000095017024125374/0000950170-24-125374-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1582313/000095017024125374/xene-20241112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-125374
- JSON: https://secwatch.observer/filing/0000950170-24-125374.json
- Plain text: https://secwatch.observer/filing/0000950170-24-125374.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.